Brief: Olema Oncology Provides Clinical Update Reflecting Strong Progress Across Op-1250 Development Program
09/06/2022 15:00
June 9 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY PROVIDES CLINICAL UPDATE REFLECTING STRONG
PROGRESS ACROSS OP-1250 DEVELOPMENT PROGRAM
* OLEMA PHARMACEUTICALS - FAVORABLE TOLERABILITY WITH NO
GRADE 3/4
NEUTROPENIA AND ENCOURAGING ANTI-TUMOR ACTIVITY ACROSS PHASE 1B
MONOTHERAPY EXPANSION
* OLEMA - CONTINUES TO BE WELL CAPITALIZED WITH SUFFICIENT
CASH TO
FUND OUR PLANNED RESEARCH AND DEVELOPMENT OPERATIONS INTO SECOND
HALF OF 2024
Source text for Eikon: ID:nGNX1SVnx1
Further company coverage: OLMA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs